title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",20220616T140943,https://www.benzinga.com/general/biotech/22/06/27737919/the-daily-biotech-pulse-roches-alzheimers-drug-fails-advisors-back-pfizer-moderna-shots-for-young,EXEL,0.147607,Neutral,0.003742
"The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",20220503T130106,https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a,EXEL,0.093507,Neutral,0.001098
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,EXEL,0.075318,Neutral,0.041398
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,EXEL,0.023102,Neutral,-0.093525
"Earnings Scheduled For May 10, 2022",20220510T091808,https://www.benzinga.com/news/earnings/22/05/27099859/earnings-scheduled-for-may-10-2022,EXEL,0.015162,Neutral,9e-06
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' - Macrogenics  ( NASDAQ:MGNX ) ,20240510T190803,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38768977/macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-w,EXEL,0.183198,Somewhat-Bearish,-0.194098
EXEL: 3 Biotech Stocks Losing Momentum as March Ends,20230329T141736,https://stocknews.com/news/exel-mgnx-pbyi-incy-3-biotech-stocks-losing-momentum-as-march-ends/,EXEL,0.241684,Somewhat-Bullish,0.245302
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ,20230613T110000,https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di,EXEL,0.019102,Neutral,0.0
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,EXEL,0.046273,Neutral,0.058004
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,EXEL,0.022494,Neutral,0.023078
Exelixis  ( EXEL )  Tops Q2 Earnings and Revenue Estimates,20230801T215511,https://www.zacks.com/stock/news/2130720/exelixis-exel-tops-q2-earnings-and-revenue-estimates,EXEL,0.405651,Somewhat-Bullish,0.277402
"The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill",20220707T140337,https://www.benzinga.com/general/biotech/22/07/27983728/the-daily-biotech-pulse-mercks-potential-seagen-buyout-expected-in-weeks-fda-holds-diamedicas-str,EXEL,0.25726,Neutral,0.012546
